Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAMAinDiab: lisdexamfetamine versus methylphenidate in children with ADHD and type 1 diabetes
2023-506862-30-00Phase 2Authorised
- Sponsor
- Medical University of Lodz
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lisdexamfetamine and methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Medical University of Lodz. Primary endpoints: Change in Conners 3 inattention score, Change in Conners 3 hyperactivity/impulsivity score and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
lisdexamfetaminemethylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on 2023-506862-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506862-30-00.